From GlobeNewswire: 2025-05-29 09:15:00

Inspira Technologies OXY B.H.N. Ltd. announced a strategic shift to focus on commercializing its FDA-cleared INSPIRA™ ART100 system, with deliveries expected to start in the second half of 2025. The ART100 has already been used to treat patients in real-world clinical settings. The company is also developing the next-generation INSPIRA™ ART500 and HYLA™ blood sensor to meet growing demand for respiratory solutions. These efforts align with global interest in scalable respiratory solutions, positioning Inspira as a key player in the critical care and MedTech landscape. For more information, visit: https://inspira-technologies.com.



Read more at GlobeNewswire: Inspira Technologies Initiates Global Commercial Rollout of